Compression or obstruction of the superior vena cava, a major vein in your body, can lead to superior vena cava syndrome, or SVCS. It’s treatable, but most cases are caused by cancer. The ...

Superior vena cava syndrome occurs when a major vein that can become blocked either with a blood clot or a cancerous tumour. ... (cancer of the lymphatic system). Symptoms in pregnancy.

Superior vena cava (SVC) syndrome is more common in people who have lung cancer or cancer that spreads to the chest. The SVC is a large vein in the upper body that drains blood away from the head ...

There are a number of common ways that cancer causes superior vena cava syndrome: A tumor in the chest could push on the superior vena cava vein. A tumor might grow into the vein and block it.

This is called superior vena cava syndrome and happens to about 2% to 4% of people with lung cancer. It's more common in people with a type of lung cancer called small-cell lung cancer.

The differential diagnosis for a large anterior mediastinal mass includes the 5 Ts: thymoma, teratoma, thyroid cancer, thoracic aortic aneurysm and tumour. In theory, any of these conditions could ...

Adenocarcinoma, squamous cell carcinoma, and large cell are among the several subtypes of NSCLC, classified by the type of cells that are affected.Compared to the other major kind of lung cancer, ...

Inferior vena cava filters are often used for prophylaxis in patients deemed to be a high risk for pulmonary embolism ... One is a RCT of anticoagulation and IVC filters in cancer patients with VTE.

The cancer has grown into the surrounding tissues or the main blood vessels such as the renal vein. It may also have grown into the large blood vessel that takes blood back to the heart (vena cava).

Background: Malignant superior vena cava syndrome (SVCS) is a clinical problem that results from the obstruction of blood flow in the superior vena cava by an underlying malignancy. It may be caused ...

Optional vena cava filters are a potentially important addition to the treatment of VTE. ... How Do CDK4/6 Inhibitors Affect HR+/HER2- Advanced Breast Cancer Outcomes in Real-World Clinical Practice?